Same Indication

Fruquintinib vs Ipilimumab

Fruquintinib vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Fruquintinib and Ipilimumab.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days.

Chemical Properties

Type: Fruquintinib β€” Small molecule; Ipilimumab β€” Antibody.